– ATH434 is a Disease Modifying Drug Candidate Targeting Alpha-Synuclein and Iron in Parkinsonian Disorders – – Topline Data Expected in Early 2025 – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 4 December 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative ...
Good morning, everyone, and thank you for joining us today here in Melbourne. It is my pleasure to share with you my Chairman’s address for Alterity Therapeutics Fiscal Year 2024 Annual General Meeting. This has been a year of significant progress and achievement for Alterity, marked by important milestones in our mission to develop disease-modifying ...
AGM 2024 Presentation
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 12 November 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the presentation of data from Alterity’s Biomarkers of progression in Multiple System Atrophy (bioMUSE) natural history study at the 35th International ...
– Peer-Reviewed Publication Describes How ATH434 Uniquely Targets Excess Iron – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 6 November 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the peer-reviewed journal, Metallomics has published data on the ...
Highlights MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 31 October 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 September 2024 (Q1 ...
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 14 October 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity will participate in a fireside chat at the 2024 Maxim Healthcare Virtual ...
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 11 October 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced promising new data related to ATH434 were presented at the Society for Neuroscience 2024 in Chicago, USA. The poster entitled, “Potent ...
– ATH434 shows promise as a disease-modifying therapy for MSA – – ATH434-202 Phase 2 interim data demonstrate stabilization of clinical symptoms and biomarkers in clinical responders – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 2 October 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease ...
XBRL 30 June 2024 filed with the SEC
